以患者为中心的肺癌筛查强化:MyLungHealth随机临床试验
研究1中,患者端EHR整合工具联合临床医生决策支持使新识别符合肺癌筛查条件者比例升至4.7%,对照为2.3%(aOR 2.19,95%CI 1.99-2.42,P<.001);研究2中低剂量CT开具率升至20.5%,对照为19.2%(aOR 1.16,95%CI 1.04-1.30,P=.008)。
要点
- 患者端工具联合医生决策支持可提高肺癌筛查资格的新识别率(4.7% vs 2.3%)。
- 已明确符合条件者中低剂量CT开具率小幅提高(20.5% vs 19.2%)。
- 相对增幅明显但绝对增幅有限,需更强干预进一步改善筛查。
核心结论
- 在初级保健EHR工作流程中整合以患者为中心的工具,可提高肺癌筛查合格患者的识别率和低剂量CT的开具率。
- 两个主要结局的相对增幅较大,但绝对增幅较为有限。
- 需要研究更强化的干预措施,以评估其进一步改善肺癌筛查的能力。
研究设计与样本
- 实用性、非分层、平行组随机临床试验,于2024年3月29日至2025年3月28日在犹他大学健康中心和纽约大学朗格尼健康中心初级保健诊所开展。
- 纳入标准为50至79岁、有记录的吸烟史、有活跃患者门户账户且过去一年有初级保健就诊的成人。
- 研究1入组条件为10至19包年、包年未知或戒烟日期缺失;研究2入组条件为20包年及以上且目前吸烟或戒烟15年内。
- 对照为临床医生端Decision Precision+工具,干预在此基础上加用MyLungHealth工具,通过患者门户以英语和西班牙语收集详细吸烟史(研究1)并提供个性化教育和风险/获益信息(研究1和2)。
主要发现
- 研究2中干预组低剂量CT开具率高于对照组:干预组2312例中474例(20.5%),对照组2262例中434例(19.2%);校正比值比1.16,95%CI 1.04-1.30,P=.008。
临床怎么用
- 在初级保健EHR中嵌入患者端吸烟史采集与个性化教育工具,可辅助识别肺癌筛查合格者并促进低剂量CT开具。
- 对已明确符合条件者,单纯患者端教育工具对低剂量CT开具的绝对提升有限,可能需要联合更强化的干预策略。
局限性
- 摘要未报告研究局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Lung cancer screening (LCS) with low-dose computed tomography (CT) remains underused in the US, partly because of incomplete smoking history documentation in electronic health records (EHRs) and limited time for shared decision-making in primary care. OBJECTIVE: To determine whether a patient-facing, EHR-integrated tool combined with clinician-facing clinical decision support improves the identification of LCS-eligible patients and the ordering of low-dose CT compared with clinician-facing tools alone. DESIGN, SETTING, AND PARTICIPANTS: This pragmatic, unstratified, randomized clinical trial with parallel groups was conducted from March 29, 2024, to March 28, 2025, at primary care clinics at University of Utah Health and New York University Langone Health. Adults aged 50 to 79 years with a documented smoking history, an active patient portal account, and a primary care visit in the preceding year were included. Study 1 enrolled patients with uncertain LCS eligibility (10 to 19 pack-years, unknown pack-years, or missing quit date); study 2 enrolled patients with documented eligibility (20 or more pack-years and currently smoking or quit smoking within 15 years). INTERVENTIONS: The control included the clinician-facing Decision Precision+ tool (preventive care reminders and a shared decision-making tool). The intervention included the Decision Precision+ tool as well as the MyLungHealth tool, which collected detailed smoking history (study 1) and delivered personalized education and risk/benefit information (studies 1 and 2) via the patient portal in English and Spanish. MAIN OUTCOMES AND MEASURES: The primary outcomes were the proportion of patients newly identified as eligible for LCS (study 1) and low-dose CT ordering rates (study 2) over 12 months. Analyses used intention-to-treat mixed-effects logistic regression. RESULTS: There were 31 303 randomized participants, including 26 729 in study 1 (13 144 [49.2%] female; 13 580 [50.8%] male; median [IQR] age, 62 [55-69] years) and 4574 in study 2 (2230 [48.8%] female; 2344 [51.2%] male; median [IQR] age, 63 [56-69] years). In study 1, the MyLungHealth tool increased new LCS eligibility identification (635 of 13 412 [4.7%] vs 308 of 13 317 [2.3%]; adjusted odds ratio, 2.19; 95% CI, 1.99-2.42; P < .001). In study 2, low-dose CT ordering was higher in the intervention arm (474 of 2312 [20.5%] vs 434 of 2262 [19.2%]; adjusted odds ratio, 1.16; 95% CI, 1.04-1.30; P = .008). CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, integrating a patient-centered tool into primary care EHR workflows increased the identification of patients eligible for LCS and the ordering of low-dose CTs. The relative increases in these primary outcomes were substantial, but absolute increases were more modest. Research on more intensive interventions is warranted to evaluate their ability to further improve LCS screening. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06338592.
引用
- Kukhareva PV, Li H, Balbin C, et al. Enhancement of Patient-Centered Lung Cancer Screening: The MyLungHealth Randomized Clinical Trial. JAMA Oncol. 2026. PMID: 41452617. doi:10.1001/jamaoncol.2025.5672
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。